Welcome to Outlook 2020.
There is much to discuss about the future of the biopharma, medtech and generics sectors as we enter a new year and new decade.
Outlook 2020 includes annual league tables for both the top 100 biopharmaceutical and top 100 medical technology companies, as well as analysis of the top 25 generics and biosimilars businesses, ranking the leaders of each sector based on their 2018 full-year financial performance. An analysis of the data for each sector can be found in the Outlook PDF. An interactive version of the Scrip 100 data, for the biopharma market, is also available here.
Monetary scrutiny is not the only reason to investigate the content of Outlook 2020. Explore all our chapters online to discover what “company culture” really means in pharma against a backdrop of intense pressure from investors for greater top-line growth. Hear from leaders at Alexion on how they have restructured the company’s R&D business and rejuvenated the pipeline. Get an expert view on how to prepare for oral explanations for regulatory submissions. Along with many more features focused on In Vivo’s five key pillars of leadership, innovation, growth, access and market intelligence.
Within the medtech realm, Outlook 2020 outlines the performance of key device and diagnostics players alongside expectations for the coming 12 months. It also features articles exploring the changing landscape in China, and how the confluence of health and technology will transform care in the 2020s.
New for 2020 are chapters on Strategy and Digital Transformation and what they mean for the biopharma and medtech industries. Included in the online offering is our Legacy chapter that includes PDFs of Scrip 100 since 2009 and copies of In Vivo’s former Outlook issues. The online selection also hosts interactive exhibits throughout various chapters and downloadable infographics.
In Vivo’s Outlook 2020 edition looks across all the key health care sectors and connects the dots: pharma, biotech, devices, diagnostics, generics, biosimilars and health tech.
Executive Editor, In Vivo
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.